NovoCure Limited Ordinary Shares (NVCR)
Stock · NASDAQ · Health Care
$14.08as of 10/16/2026
Price chart
NVCR Signal Track Record
How signals performed across all stocks →What NVCR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -2.5% | 44% | October 7, 2026 |
| Bollinger Band Breakdown | 26 | -1.1% | 38% | October 7, 2026 |
| Bollinger Band Breakout | 21 | -5.0% | 43% | July 23, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -1.8% | 33% | October 7, 2026 |
| Any 20-session window (baseline) | -2.9% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metas…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 1,605
- Website
- www.novocure.com/
Fundamentals
- 1-day range
- $13.84$14.46
- Market cap
- $1.83B
- P/E (trailing)
- —
- P/E (forward)
- -17.87
- EPS (trailing)
- $-1.31
- Dividend yield
- —
- Beta
- 1.11
- Avg. volume
- 1.44M
How NovoCure Limited Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
NovoCure Limited Ordinary Shares Competitors
Chosen by industry and closest market cap.
- NVCRNovoCure Limited Ordinary Shares$14.07▼ 2.36%Market cap $1.83BP/E —$9.82$21.45
- LMATLeMaitre Vascular Inc. Common Stock$80.82▼ 2.81%Market cap $1.85BP/E 29.17$78.22$118.01
- INSPInspire Medical Systems Inc. Common Stock$68.79▼ 1.90%Market cap $1.70BP/E 15.06$38.91$147.03
- ATRCAtriCure Inc. Common Stock$56.07▼ 2.96%Market cap $2.01BP/E 261.42$25.36$61.7
- KMTSKestra Medical Technologies Ltd. Common Stock$27.24▼ 5.02%Market cap $1.48BP/E —$17.34$30
- ATECAlphatec Holdings Inc. Common Stock$10.46▼ 4.30%Market cap $1.42BP/E —$6.82$23.29
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NVCR NovoCure Limited Ordinary Shares | $1.83B | — | $14.07 | ▼ 2.36% | $9.82$21.45 |
| LMAT LeMaitre Vascular Inc. Common Stock | $1.85B | 29.17 | $80.82 | ▼ 2.81% | $78.22$118.01 |
| INSP Inspire Medical Systems Inc. Common Stock | $1.70B | 15.06 | $68.79 | ▼ 1.90% | $38.91$147.03 |
| ATRC AtriCure Inc. Common Stock | $2.01B | 261.42 | $56.07 | ▼ 2.96% | $25.36$61.7 |
| KMTS Kestra Medical Technologies Ltd. Common Stock | $1.48B | — | $27.24 | ▼ 5.02% | $17.34$30 |
| ATEC Alphatec Holdings Inc. Common Stock | $1.42B | — | $10.46 | ▼ 4.30% | $6.82$23.29 |
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- The Bull Case For NovoCure (NVCR) Could Change Following Japan’s Optune Pax Pancreatic Cancer ApprovalYahoo · 10/10/2026
- Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic CancerYahoo · 10/1/2026
- Novocure to Report Third Quarter 2026 Financial ResultsYahoo · 10/1/2026
- Japan’s Ministry Of Health, Labour And Welfare Approves Novocure's Optune Pax To Treat Adults With Unresectable Locally Advanced Pancreatic CancerBenzinga · 10/1/2026
- NovoCure (NVCR) Stock Still Looks Cheap After Its 86% FallYahoo · 9/23/2026
- NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board ChangeYahoo · 9/23/2026
- NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-EvenYahoo · 9/18/2026
- NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- Leonard Frank X · June 30, 2026 · Grant1.9K @ $11.15
- Puri Michal Nath · June 30, 2026 · Grant1.9K @ $11.15
- Ben Arye Barak · June 30, 2026 · Grant1.3K @ $11.15
- Danziger Asaf · June 30, 2026 · Grant268 @ $11.15
- Leonard Frank X · June 4, 2026 · Sale34.3K @ $17.93
- VERNON W ANTHONY · June 3, 2026 · Grant11.6K
- David Hung · June 3, 2026 · Grant17.0K
- David Hung · June 3, 2026 · Grant11.6K
- LEUNG GABRIEL · June 3, 2026 · Grant17.0K
- LEUNG GABRIEL · June 3, 2026 · Grant11.6K
- Jeryl L. Hilleman · June 3, 2026 · Grant17.0K
- Jeryl L. Hilleman · June 3, 2026 · Grant11.6K
- Stafford Kristin · June 3, 2026 · Grant17.0K
- Stafford Kristin · June 3, 2026 · Grant11.6K
- Ocean Allyson J · June 3, 2026 · Grant17.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer
NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer. NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.